- The disease
- Respiratory insufficiency encompasses a range of conditions in which the lungs cannot adequately exchange oxygen and carbon dioxide without mechanical support. Patients may require invasive ventilation (via a breathing tube) or non-invasive ventilation (via a mask) depending on the severity and underlying cause. Neuromuscular diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are a common cause, as progressive muscle weakness eventually impairs the ability to breathe independently. Life support ventilation in this context is a long-term, often home-based therapy rather than a short-term hospital intervention.
- What the asset is trying to do
- The Astral is a bi-level ventilator device manufactured by ResMed that delivers volume-assured pressure support (VAPS) ventilation, meaning it automatically adjusts the pressure delivered to the patient to meet a target tidal volume (the amount of air moved per breath). One of the trials on record (per ClinicalTrials.gov NCT02683772) evaluated an AutoEPAP (automatic expiratory positive airway pressure) feature, which adjusts the baseline pressure to keep the upper airway open. A separate trial (per ClinicalTrials.gov NCT02847299) evaluated a hyperinflation mode intended to assist secretion clearance in neuromuscular patients. These capabilities distinguish it from simpler fixed-pressure ventilators.
- What the trial is measuring, and why it matters
- The completed Phase 3 trial (NCT02683772) enrolled up to 42 patients with upper airway obstruction, respiratory insufficiency, or respiratory failure to evaluate the Astral's VAPS AutoEPAP feature (per ClinicalTrials.gov NCT02683772). The neuromuscular study (NCT02847299) enrolled up to 20 patients and measured cough peak flow, a standard indicator of a patient's ability to clear secretions from the airway (per ClinicalTrials.gov NCT02847299). Both trials were completed with a primary completion date of March 2017 (per ClinicalTrials.gov). Both studies were device performance and feasibility trials rather than randomised pivotal efficacy studies in the conventional pharmaceutical sense.
- Efficacy benchmarks in this setting
- The Astral device is already commercially approved; comparative efficacy benchmarking in the clinical-trial pipeline sense is not applicable here. For context, in home mechanical ventilation for neuromuscular disease, published literature has examined outcomes such as survival, hospitalisations, and quality of life, but there is no single universally accepted regulatory benchmark figure for ventilator devices in this setting. Early-stage trial figures from the two completed studies listed are not statistically comparable to population-level outcomes data.